IP Library Patent Application 13553919
Patent Application
App. No. 13/553,919

Ophthalmic Compositions with an Amphoteric Surfactant, Hyaluronic Acid and Polyquaternium-1

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/553,919
Abstract

Ophthalmic compositions that comprise 0.5 ppm to 15 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride; 0.005 wt. % to 0.05 wt. % hyaluronic acid; citrate, citric acid or a mixture thereof; and 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I wherein R 1 is R or —(CH 2 ) n -NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4 is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2 − or SO 3 − . The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Claims (23)

1 . An ophthalmic composition comprising:

0.5 ppm to 15 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride;

0.005 wt. % to 0.05 wt. % hyaluronic acid;

citrate, citric acid or a mixture thereof; and

0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I

wherein R 1 is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4 is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2 − or SO 3 − .

2 . The composition of claim 1 wherein the α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-buteny]-Ω-tris(2-hydroxyethyl) ammonium chloride is present from 0.5 ppm to 5 ppm.

3 . The composition of claim 2 further comprising 0.2 ppm to 1.3 ppm of the poly(hexamethylene biguanide).

4 . The composition of claim 1 wherein R 1 is R; R 2 and R 3 are each independently selected from a C 1 -C 2 alkyl; R 4 is a C 2 -C 4 alkylene and Y is SO 3 − .

5 . The composition of claim 1 further comprising dexpanthenol, sorbitol, glycolic acid, 2-amino-2-methyl-1,3-propanediol or any mixture thereof.

6 . The composition of claim 1 further comprising propylene glycol, hydroxypropyl guar or myristamidopropyl dimethylamine.

7 . The composition of claim 1 in accordance with the Stand-Alone Procedure for Disinfecting Products based on the Disinfection Efficacy Testing for Products dated May 1, 1997 of the U.S. Food and Drug Administration, Division of Ophthalmic Devices passes primary criteria over a minimum recommended disinfection period in that that the number of bacteria recovered per mL must be reduced by a mean value of not less than 3.0 logs, and the number of mold and yeast recovered per ml must be reduced by a mean value of not less than 1.0 log within the disinfection period.

8 . An aqueous contact lens cleaning and disinfecting solution composition comprising:

0.5 ppm to 15 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride;

0.005 wt. % to 0.05 wt. % hyaluronic acid;

citrate, citric acid or a mixture thereof; and

0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I

wherein R 1 is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4 is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2 − or SO 3 − ,

wherein the cleaning and disinfecting solution in accordance with the Stand-Alone Procedure for Disinfecting Products based on the Disinfection Efficacy Testing for Products dated May 1, 1997 of the U.S. Food and Drug Administration, Division of Ophthalmic Devices passes primary criteria over a minimum recommended disinfection period in that that the number of bacteria recovered per mL must be reduced by a mean value of not less than 3.0 logs, and the number of mold and yeast recovered per ml must be reduced by a mean value of not less than 1.0 log within the disinfection period.

9 . The composition of claim 8 wherein the α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride is present from 0.5 ppm to 5 ppm.

10 . The composition of claim 9 further comprising 0.2 ppm to 1.3 ppm of the poly(hexamethylene biguanide).

11 . The composition of claim 8 wherein R 1 is R; R 2 and R 3 are each independently selected from a C 1 -C 2 alkyl; R 4 is a C 2 -C 4 alkylene and Y is SO 3 − .

12 . A method of cleaning and disinfecting a contact lens, the method comprising soaking the contact lens in the ophthalmic composition of claim 8 for at least two hours.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: XIA, ERNING; BURKE, SUSAN E.; VENKATESH, SRINI; BARNIAK, VICKI L.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028687/0223 →